Eliminate Coronary Artery Disease "ECAD"
Recruiting
Phase 2 Results N/ATrial Description
The purpose of this study is to determine whether pharmacologic lowering of low density lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate or markedly reduce the composite endpoint of incident all cause mortality, myocardial infarction, stroke or coronary revascularization.
Conditions
Interventions
- Atorvastatin (LipitorĀ®)Drug
Other Names: Lipitor Intervention Desc: 20 mg of atorvastatin daily ARM 1: Kind: Experimental Label: Atorvastatin Description: Atorvastatin(Lipitor) in addition to the usual guideline based care
Trial Design
- Allocation: Randomized
- Masking: Open Label
- Purpose: Prevention
- Endpoint: Efficacy Study
- Intervention: Parallel Assignment
Outcomes
Type | Measure | Time Frame | Safety Issue |
---|---|---|---|
Primary | Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause in the follow up period | Up to 10 years | No |
Sponsors
View Trial Locations
Recruitment
- Enrollment: 10,000
- Gender: Both
- Minimum Age: 35 Years
- Accepts Healthy Volunteers: Yes
- 3 locations, 1 country
Principal Investigators
- Dr Michael Farkouh, MD, FRCPC, MSc, FACC
Peter Munk Cardiac Centre, University Health Network
- Michael J Domanski, MD
Mount Sinai School of Medicine
- Francisco Diaz-Mitoma, MD, PhD
Advanced Medical Research Institute of Canada